2,232 results on '"Flowers, Christopher R."'
Search Results
152. Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group
153. Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
154. Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
155. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
156. Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
157. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
158. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
159. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
160. Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems
161. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
162. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.
163. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
164. Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
165. FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
166. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma
167. Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia
168. ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma
169. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
170. Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
171. Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies
172. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus.
173. CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation
174. Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
175. Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant
176. CondiS web app: imputation of censored lifetimes for machine learning-based survival analysis
177. Cutaneous/ Subcutaneous Involvement - an Immuneprivileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma.
178. Vinorelbine, Paclitaxel, Etoposide, Cisplatin, and Cytarabine (VTEPA) Is an Effective Second Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma
179. ABCL-183 Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study
180. Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study
181. B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
182. C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy
183. Prognostic modeling in diffuse large B‐cell lymphoma in the era of immunochemotherapy: Where do we go from here?
184. A Systematic Literature Review and Meta-Analysis of Radioimmunotherapy Consolidation for Patients With Untreated Follicular Lymphoma
185. To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes
186. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
187. Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
188. Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute
189. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression
190. Patterns of venous thromboembolism risk, treatment, and outcomes among patients with cancer from uninsured and vulnerable populations
191. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma
192. SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis
193. In-depth analysis of SARS-CoV-2–specific T cells reveals diverse differentiation hierarchies in vaccinated individuals
194. ACR Appropriateness Criteria[R] Recurrent Hodgkin Lymphoma: Expert Panel on Radiation Oncology--Hodgkin Lymphoma
195. Racial Differences in the Presentation and Outcomes of Chronic Lymphocytic Leukemia and Variants in the United States
196. Hepatitis C Reactivation in Patients Who Have Diffuse Large B-Cell Lymphoma Treated With Rituximab: A Case Report and Review of Literature
197. B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS
198. A conditional survival distribution-based method for censored data imputation: overcoming the hurdle in machine learning-based survival analysis
199. Improving eligibility criteria for first-line trials for patients with DLBCL using a U.S.-based Delphi-method survey
200. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.